10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Using next-generation sequencing of primary acute myeloid leukemia (AML) specimens, we identified to our knowledge the first unifying genetic network common to the two subgroups of KMT2A (MLL)-rearranged leukemia, namely having MLL fusions or partial tandem duplications. Within this network, we experimentally confirmed upregulation of the gene with the most subtype-specific increase in expression, LOC100289656, and identified cryptic MLL fusions, including a new MLL-ENAH fusion. We also identified a subset of MLL fusion specimens carrying mutations in SPI1 accompanied by inactivation of its transcriptional network, as well as frequent RAS pathway mutations, which sensitized the leukemias to synthetic lethal interactions between MEK and receptor tyrosine kinase inhibitors. This transcriptomics-based characterization and chemical interrogation of human MLL-rearranged AML was a valuable approach for identifying complementary features that define this disease.

          Related collections

          Author and article information

          Journal
          Nat. Genet.
          Nature genetics
          1546-1718
          1061-4036
          Sep 2015
          : 47
          : 9
          Affiliations
          [1 ] The Leucegene Project at the Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.
          [2 ] Division of Hematology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.
          [3 ] Department of Medicine, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
          [4 ] Centre Hospitalier Universitaire de Québec, Centre de Recherche du Centre Hospitalier de l'Université Laval and Hôpital de l'Enfant-Jésus, Quebec City, Quebec, Canada.
          [5 ] Department of Medicine, Université Laval, Quebec City, Quebec, Canada.
          [6 ] Department of Computer Science and Operations Research, Université de Montréal, Montreal, Quebec, Canada.
          [7 ] Department of Chemistry, Université de Montréal, Montreal, Quebec, Canada.
          [8 ] Department of Pharmacology, Université de Montréal, Montreal, Quebec, Canada.
          [9 ] Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.
          [10 ] Quebec Leukemia Cell Bank, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.
          Article
          ng.3371
          10.1038/ng.3371
          26237430
          c57eb16f-4678-49b0-81f1-343d074b4f98
          History

          Comments

          Comment on this article